Journal of Clinical Oncology
Articles in this Issue
KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II–IIIB (N2) non–small-cell lung cancer (NSCLC).
TPS8115 Background: Neoadjuvantpembrolizumab (pembro) + chemotherapy (CT) followed by adjuvant pembro significantly improved event-free survival (EFS), pa...
Effect of prophylactic corticosteroids on toxicities and outcomes in CAR T-cell therapy: A cohort study.
7030 Background: Common toxicities associated with infusion of Chimeric antigen receptor T-Cell (CAR T-cell) therapy include cytokine release syndrome (CR...
Long-term trastuzumab safety in tailored dose-dense anthracycline containing adjuvant chemotherapy in the PANTHER phase III trial.
12024 Background: Cardiotoxicity is a known side effect of trastuzumab and combination with anthracyclines increases the risk for cardiotoxicity. Adjuvant...
Discovery of potent degraders of pan-KRAS based on a novel KRAS binder.
3113 Background: As the most frequently mutated oncogene, KRAS alteration occurring in approximately 25% of all malignancies. Despite extensive efforts, t...
Is one year enough? Extended adjuvant dabrafenib plus trametinib for Chinese patients with resected stage III melanoma.
e21587 Background: Pathogenic BRAF mutations occur in approximately 60% of melanomas, prompting the use of dabrafenib plus trametinib (BRAF/MEK inhibitors...
Immunological correlates from phase I study of CARv3-TEAM-E in patients with recurrent glioblastoma (GBM): INCIPIENT trial.
2008 Background: Chimeric Antigen Receptor (CAR) T cells for glioblastoma (GBM) have been limited by the challenge of targeting a single tumor antigen in...
ctDNA-based clinicogenomic analysis of advanced head and neck cancer patients treated with immune checkpoint inhibitors.
6036 Background: Head and Neck cancer (HNC) is among the diverse group of malignancies affecting the head and neck region including the oral cavity. Being...
Continuous financial toxicity screening in community oncology.
1588 Background: Financial Toxicity (FT) has been repeatedly linked with adverse cancer clinical outcomes. However, screening practices vary widely, espec...
TROP2 overexpression as predictor of outcome in patients with early triple-negative breast cancer. Exploratory analysis from the GEICAM_CIBOMA trial.
582 Background: Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic strategy for triple-negative breas...
The declining but divided fight against genital organ neoplasms: Who is still left behind?
e17003 Background: Genital organ neoplasms contribute to cancer deaths, with gender-based differences in incidence and outcomes. Despite treatment advance...
Addressing clinical trial barriers in lung cancer: Patient-reported impact of resources on trial participation.
e13561 Background: Despite being the leading cause of cancer-related death, patients (pts) with lung cancer have low participation rates in clinical trial...
Personalized circulating tumor DNA analysis as predictor of efficacy of neoadjuvant therapy in HER2-positive breast cancer: A prospective study (NCT06479460).
e12604 Background: In the neoadjuvant treatment (NAT) setting, dual HER2-targeted therapy is associated with higher rates of pathologic complete response...
A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a <i>SMARCA4</i> mutation.
TPS8667 Background: Genes encoding subunits of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex are often mutated in cancer (~20%...
Trend in prostate cancer mortality in Peru during the period 2001–2020 and its prediction to 2030.
e17012 Background: According to the World Health Organization (WHO), prostate cancer ranks second in global incidence after breast cancer and fifth in mor...
Validating Navya Earthshot: An AI-enabled point-of-care solution for guideline-adherent treatment planning in a decentralized cancer care model.
1626 Background: Adherence to guidelines increases overall survival, globally. In resource-constrained settings, ~ 30% of patients receive undertreatment...
A pilot study of the ApricityCare program for early detection and management of treatment-related adverse events in patients with metastatic cancer.
TPS12146 Background: Immune checkpoint therapies (ICTs) induce T cell-mediated anti-tumor immunity and can provide long-term survival benefits for cancer...
Incidence and clinical predictors of cranial nerve palsies (CNPs) post ciltacabtagene-autoleucel (cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM).
e19508 Background: Cilta-cel was FDA-approved for RRMM patients who have received 4 lines of therapy (LOT) including a PI, an IMID and a CD38 monoclonal a...
A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
7003 Background: Approximately 30% of pts with R/R LBCL who relapse after CAR T-cell therapy experience CD19 antigen escape (Spiegel et al. Bl...
Assessment of racial/ethnic inequities in uptake of PSMA-PET imaging among patients with metastatic prostate cancer in the United States.
e13739 Background: Prostate-Specific Membrane Antigen–Positron Emission Tomography (PSMA-PET) imaging has transformed the diagnosis and treatment of prost...
IL-15RαFc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.
4606 Background: BCG is the standard therapy after transurethral resection of bladder tumor for high-risk NMIBC. IL-15 agonists can enhance the immune res...
Developing a culturally appropriate non-opioid pain coping skills training intervention for Spanish-speaking Hispanic/Latine patients with cancer-related pain: Preliminary findings.
e13773 Background: Hispanic/Latine populations in the US routinely experience disparities in cancer-related care and often have inadequate access to suita...
First-in-human study of ZGGS15, a dual-specific antibody targeting LAG-3 and TIGIT, as monotherapy in patients with advanced solid tumors.
2641 Background: ZGGS15 is a novel humanized bispecific antibody of anti LAG-3 and TIGIT. It could reverse Treg inhibition of T cells and NK cells, and ki...
Improving evidence-based treatment selection and patient-centered care in upper GI cancers: A Project ECHO initiative.
4051 Background: Accurate assessment of biomarkers (including HER2 and PD-L1) is integral to treatment selection in upper gastrointestinal (GI) cancers. H...
PENELOPE: A randomized phase II trial of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab with or without nesuparib, in patients with newly diagnosed advanced or recurrent MMR-proficient endometrial cancer.
TPS5635 Background: Clinical trials have demonstrated antitumor activity of the immune checkpoint inhibitors in endometrial cancer patients. Two landmark...
Does early phase study enrollment for pediatric oncology patients have an impact on symptom burden and quality of life (QOL)? A national Canadian study report.
10023 Background: There are few therapeutic options for pediatric patients with relapsed or refractory cancers. The impact of early phase trial enrolment...